3 assets in Toxoplasmosis

Therapeutic assets addressing Toxoplasmosis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Pyrimethamine Toxoplasmosis	National Institute of Allergy and Infectious Diseases (NIAID)	P4	BB (65)
Rovamycin Toxoplasmosis	National Institute of Allergy and Infectious Diseases (NIAID)	P4	BB (65)
Sulfadiazine Toxoplasmosis	National Institute of Allergy and Infectious Diseases (NIAID)	P4	B (62)